BREAKING🔔 A new study from G2P-Japan🇯🇵 is out at bioRxiv @biorxivpreprint. We elucidated the virological characteristics of SARS-CoV-2 JN.1 - a progeny of BA.2.86 (#Pirola). Please RT🔥 1/ biorxiv.org/content/10.110…
Cf. This is JN.1 (aka BA.2.86.1.1; in spike, JN.1 = BA.2.86 + S:L455S. Importantly, we remember that the L455 substitution, S:L455F, was observed in the XBB lineage (e.g., HK.3 and these are known as "FLip" subvariants). 2/
Transmissibility/fitness (Re):
Molecular phylogenetic-epidemic dynamics modeling led by Jumpei @jampei2 and Kaho showed that the Re of JN.1 is apparently greater than that of BA.2.86 and others, suggesting that S:L455S can contribute to the increased fitness of JN.1. 3/
ACE2 binding & pseudovirus infectivity:
ACE2 binding: BA.2.86 < JN.1
Pseudovirus infectivity: BA.2.86 > JN.1
Effect of S:L455S is different between monomeric RBD and trimerized whole S protein🤔? 4/
Immune resistance (rodent sera):
In cases of BA.2.86-infected hamster sera and BA.2.86 S-immunizesd mouse sera, the 50% neutralization titer (NT50) between BA.2.86 and JN.1 was comparable, suggesting that S:L455S does not affect the antigenicity of BA.2.86. 5/
Immune resistance (human sera):
On the other hand, the NT50 of breakthrough infection (BTI) sera with XBB.1.5 and EG.5.1 against JN.1 was significantly lower than that of HK.3 (2.6- to 3.1-fold) and BA.2.86 (3.8-fold)🔥 6/
Furthermore, JN.1 shows a robust resistance to monovalent XBB.1.5 vaccine sera🔥 These results suggest that JN.1 is one of the most immune-evading variants to date. S:L455S can contribute to increased immune evasion, which partly explains the increased Re of JN.1. 7/7
• • •
Missing some Tweet in this thread? You can try to
force a refresh
BREAKING🔔 A new study from G2P-Japan🇯🇵, led by Keiya @Keiya717, is out at @biorxivpreprint. We assessed the humoral immunity induced by JN.1 mRNA vaccines against a broad range of SARS-CoV-2 variants including JN.1, KP.3.1.1 & XEC. Please repost🔥 1/ biorxiv.org/content/10.110…
In this study, we used 2 mRNA vaccines, one is from Pfizer/BioNTech🇺🇸🇩🇪, while another is from Daiichi-Sankyo🇯🇵. The good news is that there are no significant differences between them and both broadly neutralized a variety of SARS-CoV-2 including JN.1, KP.3.1.1 and XEC. 2/
But there are two scientific interests.
First, compared to our recent study using JN.1 and KP.3.3 breakthrough (i.e. natural) infection sera, antiviral humoral immunity against KP.3 and XEC was weakly induced. However, JN.1 mNRA vaccine can. Why🤔?? 3/
BREAKING🔔 A new study from G2P-Japan🇯🇵, led by Yu in my lab, is out at bioRxiv @biorxivpreprint. We elucidated the virological characteristics of SARS-CoV-2 #XEC. Please repost🔥 1/ biorxiv.org/content/10.110…
Compared with KP.3, #XEC harbors two spike substitutions, S:T22N and S:F59S. Recombination analysis by Shusuke @KawakuboShusuke showed that XEC is a recombinant lineage of KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3) with a breakpoint at genomic position 21,738–22,599. 2/
Transmissibility/fitness (Re):
Molecular phylogenetic-epidemic dynamics modeling led by Jumpei @jampei2 and Kaho showed that the Re of #XEC is greater than that of KP.3.1.1, the most predominant variant in the world. 3/
BREAKING🔔 Here I want to quickly report our new results from G2P-Japan🇯🇵 before the preprint publication. We have elucidated the virological characteristics of SARS-CoV-2 KP.3.1.1 - a progeny of JN.1. Please RT🔥 1/
Cf.1 A new one, KP.2 (JN.1.11.1.2), has been already elucidated. 2/